📰 Gil Efron News
Page 2 - Gil Efron News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Gil Efron. Real-time updates on events, politics, business and more.
October 3, 2023
Second-line treatment with NT219 alone and in combination with cetuximab demonstrated safety and tolerability, and the combination produced confirmed partial responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
August 22, 2023
Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies expected in the coming months Cash runway...
August 22, 2023
Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies...
August 22, 2023
Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies expected in the coming months Cash runway extended into H1 2025
May 1, 2023
Bonuses 4.2.1. General Terms ... | May 1, 2023
March 24, 2023
Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEOCompany’s business plan and clinical development programs continue as planned REHOVOT, Israel, March 24, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (
February 8, 2023
Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple
February 8, 2023
Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. ...
February 3, 2023
Purple Biotech has signed an agreement to acquire Immunorizon, which develops potential multi-specific T and NK cell engager oncology therapies.
November 8, 2022
Well capitalized with cash runway through 2024 Clinical progress for both programs, CM24 and NT219 REHOVOT, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) --...